Affiliations: [a] Department of Biochemistry & Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea
| [b] Neuroscience Research Institute, Seoul National University College of Medicine, Seoul, Korea
Correspondence:
[*]
Correspondence to: Inhee Mook-Jung, PhD, Department of Biochemistry and Biomedical Sciences, Seoul National University College of Medicine, 28 Yungun-dong, Jongro-gu, Seoul, 110-799, Korea. Tel.: +82 2 740 8245; Fax: +82 2 3672 7352; E-mail: [email protected].
Note: [1] These authors contributed equally to this work.
Abstract: The evidence of strong pathological associations between type 2 diabetes and Alzheimer’s disease (AD) has increased in recent years. Contrary to suggestions that anti-diabetes drugs may have potential for treating AD, we demonstrate here that the insulin sensitizing anti-diabetes drug metformin (Glucophage®) increased the generation of amyloid-β (Aβ), one of the major pathological hallmarks of AD, by promoting β- and γ-secretase-mediated cleavage of amyloid-β protein precursor (AβPP) in SH-SY5Y cells. In addition, we show that metformin caused autophagosome accumulation in Tg6799 AD model mice. Extremely high γ-secretase activity was also detected in autophagic vacuoles, apparently a novel site of Aβ peptide generation. Together, these data suggest that metformin-induced accumulation of autophagosomes resulted in increased γ-secretase activity and Aβ generation. Additional experiments indicated that metformin increased phosphorylation of AMP-activated protein kinase, which activates autophagy by suppressing mammalian target of rapamycin (mTOR). The suppression of mTOR then induces the abnormal accumulation of autophagosomes. We conclude that metformin, an anti-diabetes drug, may exacerbate AD pathogenesis by promoting amyloidogenic AβPP processing in autophagosomes.
Keywords: Alzheimer’s disease, amyloid-β peptides, amyloid-β protein precursor, autophagy, metformin
